Aummune
About
Aummune is a clinical-stage company developing a novel, individualized immunotherapy for solid tumors. Their proprietary platform utilizes an efficacy-driven selection process to create patient-specific tri-functional oligonucleotide drugs that induce cancer cell death and activate immune responses. This approach aims to provide a new class of therapy for a broad spectrum of cancer indications.
Key facts
At-a-glance profile data
- Website
- aummune.com
- Headquarters
- San Diego, United States
- Founded
- 2017
- Employees
- 6
- Total funding
- $10M (Series A)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 28 Sept 2021 | Series A | $10M | - |
Tech stack
Detected on aummune.com, last scanned 18 Sept 2026. Run your own scan
- Frontend
- jQuery
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
Add first review
Frequently asked
How much funding has Aummune raised?
Aummune has raised a total of $10M in funding. The most recent round on record is Series A.
How many employees does Aummune have?
Aummune has approximately 6 people on record.